

Product Name: LY2857785 Revision Date: 01/10/2021

Product Data Sheet

LY2857785

Cat. No.: B8002

CAS No.: 1619903-54-6
Formula: C26H36N6O


M.Wt: 448.6

Synonyms:

Target: Cell Cycle/Checkpoint

Pathway: Cyclin-Dependent Kinases

Storage: Desiccate at -20°C



Solvent & Solubility

insoluble in H2O; \geqslant 13.87 mg/mL in EtOH with gentle warming; \geqslant 2.63 mg/mL in DMSO with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.2292 mL	11.1458 mL	22.2916 mL
	5 mM	0.4458 mL	2.2292 mL	4.4583 mL
	10 mM	0.2229 mL	1.1146 mL	2.2292 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	CDK9 inhibitor		
IC ₅₀ & Target			
In Vitro	Cell Viability Assay		
	Cell Line:	Human bone marrow myeloid progenitor cells	
	Preparation method:	This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in	
		the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.	

	Reacting conditions:	Cells were treated with varying concentrations of compound for varying			
		durations ranging from 4 to 24 hours.			
	Applications:	LY2857785 inhibited hematologic tumor cell (human bone marrow myeloid			
		progenitor cells) proliferation.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	Human cancer cells U87MG, MV-4-11, A375, and HCT116 xenograft rat			
	PE	models			
	Dosage form:	4, 8, 18 mg/kg. i.v. every 3 days.			
	Applications:	LY2857785 demonstrates potent antitumor growth efficacy in preclinical tumor			
		models (U87MG, MV-4-11, A375, and HCT116 xenograft rat models).			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
		slightly differ with the theoretical value. This is caused by an experimental			
		system error and it is normal.			
	40.	10.			
Droduci	Citations	APE BIO			
Product Citations		APL			

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13(6):1442-56.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com













APE BIO



APE BIO